Funds for exploration of Moon, Mars should be raised abroad — RoscosmosScience & Space January 24, 11:58
Syria talks in Astana to end on Tuesday — sourceWorld January 24, 11:50
Syrian opposition says no plans to sign Astana meeting communiqueWorld January 24, 10:34
Astana talks may continue on Wednesday, Syrian opposition saysWorld January 24, 9:14
Syria peace talks in Astana enter second dayWorld January 24, 8:52
China deploys intercontinental missiles near Russian border — mediaWorld January 24, 7:58
Russian army engineers defuse almost 500 improvised explosives in eastern AleppoMilitary & Defense January 24, 6:56
Printing house in Kiev releases map of Ukraine leaving out CrimeaWorld January 24, 4:34
Title for Episode VIII of world’s famous saga ‘Star Wars’ revealedSociety & Culture January 23, 21:19
NOVOSIBIRSK, November 14 (Itar-Tass) - Scientists at Russia's SibEnzyme enterprise in the Siberian city of Novosibirsk have developed a brand new method to diagnose oncological diseases at very early stages, the company’s chief executive, Yevgeny Dubinin, told Itar-Tass at the international forum for technological development Technoprom.
The new method allows to detect cancer cells even if the sample under scrutiny (blood, phlegm, urine or smear) contains only few DNA molecules with abnormally methylated (abnormally working, ‘silent’ genes), according to Dubinin.
The company’s enzyme, whose patented technology detects methylated genes, is used as a tumor marker. Analysis is simple and reliable - carried out on standard equipment, in one vial and in three stages, it takes only about four hours.
“There is almost no early cancer diagnostic in Russia, while treating the disease when it is detected at the third and fourth stages yields little effect,” Dubinin said.
The new method will be indispensable for oncological centres, diagnostic laboratories, and other medical institutions, the director added. The estimated market volume is about 5.5 million examinations and 1.8 million for rare types of cancer.